Pancreatic Cancer Research

ResearcherOntario Institute for Cancer ResearchActive in the last 2 years

Faiyaz Notta

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5748-3985; OpenAlex author ID A5061402791. Sources: OpenAlex.

Their work

Papers
61 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
244
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 7 papers · 2021: 10 papers · 2022: 5 papers · 2023: 7 papers · 2024: 3 papers · 2025: 12 papers · 2026: 11 papers

Papers 50 of 61

  1. ZNF274 constrains lineage plasticity and drives intrinsic resistance to CDK7 inhibitors in pancreatic cancer. Co-author DOI 10.1038/s41467-026-73380-x↗
  2. Developmental and MAPK-responsive transcription factors regulate distinct malignant cell states and associated genetic dependencies in pancreatic cancer. Co-author DOI 10.1038/s41588-026-02714-8↗
  3. Clinical and Molecular Correlates of Circulating Tumor Fraction in Patients with Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-26-0793↗
  4. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  5. Examination of DNA methylation patterns in pancreatic ductal adenocarcinoma Co-author DOI 10.21203/rs.3.rs-10421877/v1↗
  6. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. Co-author DOI 10.3389/frai.2026.1873681↗
  7. Transcriptomic, Genomic, and Clinical Characterization of Morphological Classes in Localized and Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.04.07.717011↗
  8. Extra-lineage tissue programs define the transcription states of human pancreatic cancer Last author DOI 10.64898/2026.04.29.721655↗
  9. Multimodal Machine Learning for Predicting Outcomes in the PASS-01 Trial of Systemic Therapy for Metastatic Pancreatic Cancer Co-author DOI 10.64898/2026.08.24.26360900↗
  10. HMGA2 Expression in Pancreatic Ductal Adenocarcinoma Controls Tumor Microenvironment and Immunosuppression via IL1α Co-author DOI 10.64898/2026.10.02.754697↗
  11. Loss of the Y chromosome drives basal identity and metastatic potential via epigenetic reprogramming in pancreatic cancer Co-author DOI 10.64898/2026.10.06.756936↗
  12. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  13. Multi-omics whole-genome characterization of the copy number landscape of metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.isci.2025.113176↗
  14. HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Co-author DOI 10.1038/s41467-025-60129-1↗
  15. Whole genome and transcriptome profiling in advanced pancreatic cancer patients on the COMPASS trial. Co-author DOI 10.1038/s41467-025-60808-z↗
  16. Correction: Analysis of an engineered organoid model of pancreatic cancer identifies hypoxia as a contributing factor in determining transcriptional subtypes. Co-author DOI 10.1038/s41598-025-18193-6↗
  17. Analysis of an engineered organoid model of pancreatic cancer identifies hypoxia as a contributing factor in determining transcriptional subtypes. Co-author DOI 10.1038/s41598-025-98344-x↗
  18. The tandem duplicator phenotype may be a novel targetable subgroup in pancreatic cancer. Co-author DOI 10.1038/s41698-025-00888-8↗
  19. Integrated spatial proteomics of human PDAC uncovers an expanded tumour-immune-stroma spectrum with genomic associations Co-author DOI 10.1101/2025.08.15.670565↗
  20. The subclonal footprint of pervasive early dissemination in pancreatic cancer Last author DOI 10.1101/2025.11.27.690823↗
  21. HMGA2 Expression Predicts Subtype, Survival, and Treatment Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-24-2200↗
  22. PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metastatic Panc… Co-author DOI 10.1200/jco-25-00436↗
  23. Erratum: PASS-01: Randomized Phase II Trial of Modified FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel and Molecular Correlatives for Previously Untreated Metast… Co-author DOI 10.1200/jco-25-02195↗
  24. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer. Co-author DOI 10.1016/j.ccell.2024.08.002↗
  25. In vivo CRISPR screens reveal SCAF1 and USP15 as drivers of pancreatic cancer. Co-author DOI 10.1038/s41467-024-49450-3↗
  26. Cytidine deaminases APOBEC3C and APOBEC3D promote DNA replication stress resistance in pancreatic cancer cells. Co-author DOI 10.1038/s43018-024-00742-z↗
  27. Systemic inflammatory prognostic scores in advanced pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-023-02214-0↗
  28. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2023.02.049↗
  29. p73 activates transcriptional signatures of basal lineage identity and ciliogenesis in pancreatic ductal adenocarcinoma Co-author DOI 10.1101/2023.04.20.537667↗
  30. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  31. Molecular characterisation of pancreatic ductal adenocarcinoma with NTRK fusions and review of the literature. Co-author DOI 10.1136/jclinpath-2021-207781↗
  32. hENT1 as a Predictive Biomarker in PDAC-Response. Co-author DOI 10.1158/1078-0432.ccr-23-0887↗
  33. Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting. Co-author DOI 10.1158/2159-8290.cd-22-0412↗
  34. Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma. Co-author DOI 10.1038/s41467-022-33718-7↗
  35. Correction: GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-22-1272↗
  36. hENT1 Expression Predicts Response to Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-22-2576↗
  37. MYC Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-20-1826↗
  38. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU). Co-author DOI 10.3389/fimmu.2022.1060957↗
  39. Spatially confined sub-tumor microenvironments in pancreatic cancer. Co-author DOI 10.1016/j.cell.2021.09.022↗
  40. Genomic sequencing to inform therapy in advanced pancreatic cancer: A systematic review and meta-analysis of prospective studies. Co-author DOI 10.1016/j.ctrv.2021.102310↗
  41. The value of GATA6 immunohistochemistry and computer-assisted diagnosis to predict clinical outcome in advanced pancreatic cancer. Co-author DOI 10.1038/s41598-021-94544-3↗
  42. APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. Co-author DOI 10.1038/s43018-021-00268-8↗
  43. Genomic Features and Classification of Homologous Recombination Deficient Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2021.01.220↗
  44. NOX4 links metabolic regulation in pancreatic cancer to endoplasmic reticulum redox vulnerability and dependence on PRDX4. Co-author DOI 10.1126/sciadv.abf7114↗
  45. Clinical and genomic characterisation of mismatch repair deficient pancreatic adenocarcinoma. Co-author DOI 10.1136/gutjnl-2020-320730↗
  46. Delving into Early-onset Pancreatic Ductal Adenocarcinoma: How Does Age Fit In? Co-author DOI 10.1158/1078-0432.ccr-20-1042↗
  47. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics. Co-author DOI 10.1158/1078-0432.ccr-20-2831↗
  48. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  49. Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Last author DOI 10.1038/s41588-019-0566-9↗
  50. Author Correction: Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution. Last author DOI 10.1038/s41588-020-0588-3↗

Closest collaborators

The 25 strongest of 244 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Steve Gallinger · 44 shared papers, 2016–2026 · strength 5.74
  2. Grainne Mary O'Kane · 36 shared papers, 2018–2026 · strength 4.92
  3. Jennifer Jane Knox · 33 shared papers, 2018–2026 · strength 4.46
  4. Robert C. Grant · 29 shared papers, 2017–2026 · strength 4.15
  5. Sandra Elisabeth Fischer · 19 shared papers, 2018–2026 · strength 2.24
  6. Erica S. Tsang · 12 shared papers, 2021–2026 · strength 1.99
  7. George Zogopoulos · 16 shared papers, 2016–2026 · strength 1.75
  8. David Arthur Tuveson · 11 shared papers, 2020–2026 · strength 1.66
  9. Barbara T. Grünwald · 11 shared papers, 2020–2026 · strength 1.58
  10. Daniel John Renouf · 13 shared papers, 2020–2026 · strength 1.58
  11. Michelle Chan‐Seng‐Yue · 11 shared papers, 2016–2026 · strength 1.34
  12. David F. Schaeffer · 11 shared papers, 2020–2026 · strength 1.25
  13. Eugenia Flores Figueroa · 7 shared papers, 2020–2026 · strength 1.19
  14. Joanna M. Karasinska · 10 shared papers, 2020–2026 · strength 1.16
  15. James Thomas Topham · 10 shared papers, 2020–2026 · strength 1.16
  16. Yifan Wang · 9 shared papers, 2020–2025 · strength 1.02
  17. Ayelet Borgida · 9 shared papers, 2016–2026 · strength 0.94
  18. Spring Holter · 7 shared papers, 2018–2026 · strength 0.93
  19. Naomi Yamamoto · 4 shared papers, 2025–2026 · strength 0.83
  20. Stephanie Dobersch · 4 shared papers, 2025–2026 · strength 0.83
  21. Sita Kugel · 4 shared papers, 2025–2026 · strength 0.83
  22. Hartland Warren Jackson · 4 shared papers, 2025–2026 · strength 0.80
  23. Sabrina Ge · 4 shared papers, 2023–2026 · strength 0.77
  24. Raymond Jang · 5 shared papers, 2021–2025 · strength 0.75
  25. Ravi Ramjeesingh · 5 shared papers, 2021–2026 · strength 0.73

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.